Financial Results - Enveric Biosciences, Inc. reported its financial results for the fourth quarter and fiscal year ended December 31, 2024[4]. - Specific financial metrics and performance data were included in the press release, which is referenced as Exhibit 99.1[4]. - The financial statements and exhibits related to the report are detailed in Item 9.01[6]. Corporate Update - The company issued a press release on March 31, 2025, providing a corporate update alongside the financial results[4]. - The report was signed by Joseph Tucker, Ph.D., the Chief Executive Officer of Enveric Biosciences, Inc.[9]. Regulatory Information - The report is not deemed "filed" under the Securities Exchange Act of 1934, and it will not be incorporated by reference into any registration statement[5]. - The company has not indicated whether it is an emerging growth company[3]. Product and Market Information - The report does not provide specific user data or future guidance in the available content[4]. - No new products, technologies, market expansions, or acquisition strategies were mentioned in the provided documents[4]. Trading Information - The company is registered under the trading symbol ENVB on The Nasdaq Stock Market[2].
Enveric Biosciences(ENVB) - 2024 Q4 - Annual Results